Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Musselman K, Glynn S, Mosquera JM, Elemento O, Sboner A, Beltran H, et al. Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma. Gynecol Oncol Rep. 2019;28:54-57.

Guerrero-Preston R, Lawson F, Rodriguez-Torres S, Noordhuis MG, Pirini F, Manuel L, et al. Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients. Cancer Prev Res (Phila). 2019;12(4):255-270.

Crowe EP, DeSimone RA. Transfusion support and alternatives for Jehovah's Witness patients. Curr Opin Hematol. 2019;26(6):473-479.

Kahn RM, Gordhandas S, Chapman-Davis E, Margolskee E, Matrai C, Chadburn A, et al. Acute Myeloid Leukemia Presenting as Myeloid Sarcoma with a Predisposition to the Gynecologic Tract. Case Rep Oncol Med. 2019;2019:4189275.

Zhu H, Wang M, Dong Y, Hu H, Zhang Q, Qiao C, et al. Detection of non-criteria autoantibodies in women without apparent causes for pregnancy loss. J Clin Lab Anal. 2019;33(9):e22994.

Magruder M, Sholi AN, Gong C, Zhang L, Edusei E, Huang J, et al. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat Commun. 2019;10(1):5521.

Acosta-Gonzalez G, Ouseph M, Lombardo K, Lu S, Glickman J, Resnick MB. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression. Hum Pathol. 2019;83:115-123.

Starza ID, De Novi LA, Santoro A, Salemi D, Tam W, Cavalli M, et al. Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(11):2838-2840.

Farber G, Parks MM, Guahmich NL, Zhang Y, Monette S, Blanchard SC, et al. ADAM10 controls the differentiation of the coronary arterial endothelium. Angiogenesis. 2019;22(2):237-250.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, et al. Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. J Natl Compr Canc Netw. 2019;17(3):194-200.